Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

Hinge Health Inc. and a group of investors raised $437 million in the digital physical therapy provider’s US initial public ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

At the World Health Assembly, 193 members nations voted to adopt a treat calling for better preventive measures and global ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

While President Donald Trump may wish he lives and works in the Hogwarts School of Witchcraft and Wizardry and has Harry ...

The Dementia Discovery Fund ("DDF"), managed by SV Health Investors, today announced the final closing of its second fund, DDF-2, with $269m in commitments. DDF is the world's largest family of ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

In 2024 alone, Singapore secured S$13.5 billion in fixed asset investment commitments, with the biomedical sector ...